Pacific Biosciences Of Stock Alpha and Beta Analysis
| PACB Stock | USD 1.80 0.03 1.69% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Pacific Biosciences of. It also helps investors analyze the systematic and unsystematic risks associated with investing in Pacific Biosciences over a specified time horizon. Remember, high Pacific Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Pacific Biosciences' market risk premium analysis include:
Beta 2.67 | Alpha 0.15 | Risk 6.76 | Sharpe Ratio 0.0594 | Expected Return 0.4 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Pacific |
Pacific Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Pacific Biosciences market risk premium is the additional return an investor will receive from holding Pacific Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Pacific Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Pacific Biosciences' performance over market.| α | 0.15 | β | 2.67 |
Pacific Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Pacific Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Pacific Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Pacific Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Pacific Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Pacific Biosciences shares will generate the highest return on investment. By understating and applying Pacific Biosciences stock market price indicators, traders can identify Pacific Biosciences position entry and exit signals to maximize returns.
Pacific Biosciences Return and Market Media
The median price of Pacific Biosciences for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 1.75 with a coefficient of variation of 17.1. The daily time series for the period is distributed with a sample standard deviation of 0.31, arithmetic mean of 1.82, and mean deviation of 0.24. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Ericson William W. of 32179 shares of Pacific Biosciences at 1.65 subject to Rule 16b-3 | 09/03/2024 |
2 | Disposition of 98907 shares by Henry Christian O of Pacific Biosciences at 1.746 subject to Rule 16b-3 | 09/16/2024 |
3 | Acquisition by Livingston Randall S of 22821 shares of Pacific Biosciences subject to Rule 16b-3 | 09/27/2024 |
4 | Investors Are Invited To Join The Schall Law Firms Inquiry Into Pacific Biosciences of California Inc For Possible Securities Fraud | 10/04/2024 |
5 | PacBio Onso Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program | 10/22/2024 |
6 | Acquisition by Ericson William W. of 25775 shares of Pacific Biosciences at 11.94 subject to Rule 16b-3 | 11/06/2024 |
7 | Pacific Biosciences of California Reports Q3 Loss, Misses Revenue Estimates | 11/07/2024 |
8 | Pacific Biosciences Q3 Earnings Taking a Look at Key Metrics Versus Estimates | 11/08/2024 |
9 | Pacific Biosciences of California Given New 6.00 Price Target at Scotiabank | 11/12/2024 |
10 | Pacific Biosciences of California, Inc. Among the Best Genomics Stocks to Buy Right Now | 11/20/2024 |
About Pacific Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Pacific or other stocks. Alpha measures the amount that position in Pacific Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 6.51 | 6.59 | 9.81 | 6.34 | Days Of Inventory On Hand | 125.31 | 231.98 | 140.02 | 158.79 |
Pacific Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Pacific Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pacific Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Pacific Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Pacific Biosciences. Please utilize our Beneish M Score to check the likelihood of Pacific Biosciences' management manipulating its earnings.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Pacific Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Pacific Biosciences Backtesting, Pacific Biosciences Valuation, Pacific Biosciences Correlation, Pacific Biosciences Hype Analysis, Pacific Biosciences Volatility, Pacific Biosciences History and analyze Pacific Biosciences Performance. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Pacific Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.